For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
IND234 substudy D: A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - A Substudy of IND234 is closed to accrual however this substudy, treatment and follow up of patients will continue according to the protocol. Please note the IND234 main study and other substudies remain open to accrual.
EN10 (RAINDO BLUE & TAPER) is a new Canadian clinical trial that is applying state-of-the-art molecular testing to classify post-surgery treatments in early-stage endometrial cancer.
The purpose of this study is to identify people at low risk of cancer recurrence based on the molecular features of their tumours. These individuals may safely receive less radiotherapy or may require no radiotherapy or chemotherapy after surgery.
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative held their annual research workshop on December 1 & 2nd in Waikiki Hawaii. In addition to the main workshop, a satellite guidelines panel was conducted in conjunction with NANETS to develop consensus statements for predictive and prognostic biomarkers in metastatic NENs.
The San Antonio Breast Cancer Symposium (SABCS) is an annual event cosponsored by the AACR and UT Health San Antonio’s Mays Cancer Center. The meeting hosts about 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for the important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
American Society of Hematology Annual Meeting and Exposition is the world’s most comprehensive hematology event of the year. ASH is a professional society concerned with the causes and treatments of blood disorders.
